These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38511103)

  • 1. Effects of Low-Dose Glucagon on Subcutaneous Insulin Absorption in Pigs.
    Teigen IA; Åm MK; Riaz M; Christiansen SC; Carlsen SM
    Curr Ther Res Clin Exp; 2024; 100():100736. PubMed ID: 38511103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasodilatory effects of glucagon: A possible new approach to enhanced subcutaneous insulin absorption in artificial pancreas devices.
    Teigen IA; Riaz M; Åm MK; Christiansen SC; Carlsen SM
    Front Bioeng Biotechnol; 2022; 10():986858. PubMed ID: 36213069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of glucagon after intravenous, intraperitoneal and subcutaneous administration in a pig model.
    Teigen IA; Åm MK; Carlsen SM; Christiansen SC
    Basic Clin Pharmacol Toxicol; 2022 Jun; 130(6):623-631. PubMed ID: 35416407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of glucagon on local subcutaneous blood flow in non-diabetic volunteers; a proof-of-concept study.
    Åm MK; Munkerud EY; Berge MH; Christiansen SC; Carlsen SM
    Eur J Pharmacol; 2022 Jul; 926():175045. PubMed ID: 35609678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A composite model of glucagon-glucose dynamics for in silico testing of bihormonal glucose controllers.
    Herrero P; Georgiou P; Oliver N; Reddy M; Johnston D; Toumazou C
    J Diabetes Sci Technol; 2013 Jul; 7(4):941-51. PubMed ID: 23911175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal and subcutaneous glucagon delivery in anaesthetized pigs: effects on circulating glucagon and glucose levels.
    Åm MK; Dirnena-Fusini I; Fougner AL; Carlsen SM; Christiansen SC
    Sci Rep; 2020 Aug; 10(1):13735. PubMed ID: 32792580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal, subcutaneous and intravenous glucagon delivery and subsequent glucose response in rats: a randomized controlled crossover trial.
    Dirnena-Fusini I; Åm MK; Fougner AL; Carlsen SM; Christiansen SC
    BMJ Open Diabetes Res Care; 2018; 6(1):e000560. PubMed ID: 30487972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
    Gutniak MK; Linde B; Holst JJ; Efendić S
    Diabetes Care; 1994 Sep; 17(9):1039-44. PubMed ID: 7988303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
    Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food intake rather than blood glucose levels affects the pharmacokinetic profile of insulin aspart in pigs.
    Gradel AKJ; Kildegaard J; Porsgaard T; Lykkesfeldt J; Refsgaard HHF
    Basic Clin Pharmacol Toxicol; 2021 Jun; 128(6):783-794. PubMed ID: 33626236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes.
    Herzig D; Dehais J; Prost JC; Nakas CT; Stettler C; Bally L; Hovorka R
    Diabetes Technol Ther; 2020 Sep; 22(9):691-696. PubMed ID: 31999478
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation.
    Haidar A; Duval C; Legault L; Rabasa-Lhoret R
    J Diabetes Sci Technol; 2013 Nov; 7(6):1507-12. PubMed ID: 24351176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
    Becker RH; Stechl J; Steinstraesser A; Golor G; Pellissier F
    Diabetes Metab Res Rev; 2015 Sep; 31(6):610-8. PubMed ID: 25773712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feasibility study of bihormonal closed-loop blood glucose control using dual subcutaneous infusion of insulin and glucagon in ambulatory diabetic swine.
    El-Khatib FH; Jiang J; Damiano ER
    J Diabetes Sci Technol; 2009 Jul; 3(4):789-803. PubMed ID: 20144330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects.
    Edwards CM; Todd JF; Ghatei MA; Bloom SR
    Clin Sci (Lond); 1998 Dec; 95(6):719-24. PubMed ID: 9831697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.